Validated gene targets associated with curatively treated advanced serous ovarian carcinoma

Gynecologic Oncology

Volumn 128, Issue 3, 2013, Pages 512-517

  Barlin, Joyce N ^a   Jelinic, Petar ^a   Olvera, Narciso ^a   Bogomolniy, Faina ^a   Bisogna, Maria ^a   Dao, Fanny ^a   Barakat, Richard R ^a   Chi, Dennis S ^a   Levine, Douglas A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Gene expression; Long term survivors; Outcome; Ovarian cancer; TCGA

Indexed keywords

CHOLINE ETHANOLAMINE PHOSPHOTRANSFERASE 1; CHROMATIN MODIFYING PROTEIN 4A; CYTOCHROME P450 4B1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOTRANSFERASE; PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; GENE EXPRESSION; GENE TARGETING; HIGH GRADE SEROUS OVARIAN CANCER; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SIGNAL TRANSDUCTION; SURVIVAL TIME;

ADULT; AGED; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; SURVIVORS; TREATMENT OUTCOME;

EID: 84873600251     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.11.018     Document Type: Article

References (29)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. W.J. Hoskins, W.P. McGuire, M.F. Brady, H.D. Homesley, W.T. Creasman, and M. Berman The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma Am J Obstet Gynecol 170 1994 974 979 [discussion 979-80]
3. R.F. Ozols, B.N. Bundy, B.E. Greer, J.M. Fowler, D. Clarke-Pearson, and R.A. Burger Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 21 2003 3194 3200
4. W.P. McGuire, W.J. Hoskins, M.F. Brady, P.R. Kucera, E.E. Partridge, and K.Y. Look Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1996 1 6
5. D.S. Chi, F. Musa, F. Dao, O. Zivanovic, Y. Sonoda, and M.M. Leitao An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT) Gynecol Oncol 124 2012 10 14
6. MAQC Consortium, L. Shi, L.H. Reid, W.D. Jones, R. Shippy, and J.A. Warrington The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements Nat Biotechnol 24 2006 1151 1161
7. T. Bonome, J.Y. Lee, D.C. Park, M. Radonovich, C. Pise-Masison, and J. Brady Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary Cancer Res 65 2005 10602 10612
8. A. Berchuck, E.S. Iversen, J.M. Lancaster, J. Pittman, J. Luo, and P. Lee Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers Clin Cancer Res 11 2005 3686 3696
9. A. Berchuck, E.S. Iversen, J. Luo, J.P. Clarke, H. Horne, and D.A. Levine Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome Clin Cancer Res 15 2009 2448 2455
10. T.R. Network Integrated genomic analyses of ovarian carcinoma Nature 474 2011 609 615
11. Institute NC http://provocativequestions.nci.nih.gov/
12. T. Bonome, D.A. Levine, J. Shih, M. Randonovich, C.A. Pise-Masison, and F. Bogomolniy A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer Cancer Res 68 2008 5478 5486
13. G.K. Geiss, R.E. Bumgarner, B. Birditt, T. Dahl, N. Dowidar, and D.L. Dunaway Direct multiplexed measurement of gene expression with color-coded probe pairs Nat Biotechnol 26 2008 317 325
14. P.P. Reis, L. Waldron, R.S. Goswami, W. Xu, Y. Xuan, and B. Perez-Ordonez mRNA transcript quantification in archival samples using multiplexed, color-coded probes BMC Biotechnol 11 2011 46
15. R. Simon, A. Lam, M.C. Li, M. Ngan, S. Menenzes, and Y. Zhao Analysis of gene expression data using BRB-ArrayTools Cancer Inform 3 2007 11 17
16. M.R. Milam, R. Harrell, R. Bassett, L.P. Parker, D.S. Metzinger, and P.T. Ramirez Clinical characteristics of patients with prolonged disease-free survival after primary treatment in advanced ovarian cancer: a brief report Int J Gynecol Cancer 21 2011 475 477
17. S. Paik, S. Shak, G. Tang, C. Kim, J. Baker, and M. Cronin A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 2004 2817 2826
18. L.J. van 't Veer, H. Dai, M.J. van de Vijver, Y.D. He, A.A. Hart, and M. Mao Gene expression profiling predicts clinical outcome of breast cancer Nature 415 2002 530 536
19. L.C. Hartmann, K.H. Lu, G.P. Linette, W.A. Cliby, K.R. Kalli, and D. Gershenson Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy Clin Cancer Res 11 2005 2149 2155
20. D. Spentzos, D.A. Levine, M.F. Ramoni, M. Joseph, X. Gu, and J. Boyd Gene expression signature with independent prognostic significance in epithelial ovarian cancer J Clin Oncol 22 2004 4700 4710
21. A.A. Jazaeri, C.S. Awtrey, G.V. Chandramouli, Y.E. Chuang, J. Khan, and C. Sotiriou Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers Clin Cancer Res 11 2005 6300 6310
22. E. Jabbour, J. Cortes, and H. Kantarjian Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors Cancer 117 2011 897 906
23. B.R. Baer, and A.E. Rettie CYP4B1: an enigmatic P450 at the interface between xenobiotic and endobiotic metabolism Drug Metab Rev 38 2006 451 476
24. J.F. Deeken, T. Cormier, D.K. Price, T.M. Sissung, S.M. Steinberg, and K. Tran A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform Pharmacogenomics J 10 2010 191 199
25. K. Glunde, Z.M. Bhujwalla, and S.M. Ronen Choline metabolism in malignant transformation Nat Rev Cancer 11 2011 835 848
26. A. Yalcin, B. Clem, S. Makoni, A. Clem, K. Nelson, and J. Thornburg Selective inhibition of choline kinase simultaneously attenuates MAPK and PI3K/AKT signaling Oncogene 29 2010 139 149
27. E. Iorio, D. Mezzanzanica, P. Alberti, F. Spadaro, C. Ramoni, and S. D'Ascenzo Alterations of choline phospholipid metabolism in ovarian tumor progression Cancer Res 65 2005 9369 9376
28. E. Iorio, A. Ricci, M. Bagnoli, M.E. Pisanu, G. Castellano, and M. Di Vito Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells Cancer Res 70 2010 2126 2135
29. T. Shi, Y. Dong, J. Li, P. Gao, D. Fu, and D. Ma High-throughput screening identifies CHMP4A associated with hypoxia-inducible factor 1 Life Sci 87 2010 604 608